A new trading day began on Friday, with NewAmsterdam Pharma Company NV (NASDAQ: NAMS) stock price down -3.67% from the previous day of trading, before settling in for the closing price of $18.28. NAMS’s price has ranged from $14.06 to $27.29 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 34.27%. Meanwhile, its annual earnings per share averaged 32.30%. With a float of $62.27 million, this company’s outstanding shares have now reached $112.17 million.
Considering the fact that the conglomerate employs 68 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 93.52%, operating margin of -248.3%, and the pretax margin is -309.09%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of NewAmsterdam Pharma Company NV is 44.54%, while institutional ownership is 57.55%. The most recent insider transaction that took place on May 15 ’25, was worth 5,598,975. Before that another transaction happened on Apr 11 ’25, when Company’s Affiliate proposed sale 1,433,193 for $15.12, making the entire transaction worth $21,669,878.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 32.30% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Here are NewAmsterdam Pharma Company NV’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 19.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.88, a number that is poised to hit -0.49 in the next quarter and is forecasted to reach -1.92 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Compared to the last year’s volume of 0.87 million, its volume of 0.42 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 10.74%. Additionally, its Average True Range was 1.15.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 27.86%, which indicates a significant increase from 3.51% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.80% in the past 14 days, which was lower than the 55.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $19.05, while its 200-day Moving Average is $19.93. Nevertheless, the first resistance level for the watch stands at $18.23 in the near term. At $18.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $19.21. If the price goes on to break the first support level at $17.25, it is likely to go to the next support level at $16.88. Should the price break the second support level, the third support level stands at $16.27.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
With a market capitalization of 1.98 billion, the company has a total of 109,818K Shares Outstanding. Currently, annual sales are 45,560 K while annual income is -241,600 K. The company’s previous quarter sales were 2,980 K while its latest quarter income was -39,530 K.
